title: Statins for hemodialysis patients with diabetes? Long-term follow-up endorses the original conclusions of the 4D Study.
abstract: The clinical benefits of statins in dialysis patients are unproven. New follow-up data from the 4D Study indicate no clear reduction in cardiovascular events among patients with type-2 diabetes. Assessing outcomes 7.4 years beyond the randomization period (20 mg atorvastatin versus placebo), no differences in a composite cardiovascular outcome were observed and no safety concerns emerged. Current Kidney Disease: Improving Global Outcomes (KDIGO) guidelines do not need updating based on these new data.
authors.affiliation: Centre for Nephrology, University College London, London, UK. Electronic address: d.wheeler@ucl.ac.uk.
authors.forename: David C
authors.initials: DC
authors.lastname: Wheeler
authors.affiliation: Department of Medicine, Hennepin County Medical Center, Minneapolis, Minnesota, USA.
authors.forename: Bertram L
authors.initials: BL
authors.lastname: Kasiske
mesh_terms: D002318:Cardiovascular Diseases; D005500:Follow-Up Studies; D006538:Heptanoic Acids; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011758:Pyrroles; D006435:Renal Dialysis
chemical_list: D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011758:Pyrroles